Suppr超能文献

ViroSeq HIV-1基因分型系统版本2中RNA提取模块的修改与替换:对检测灵敏度和复杂度的影响

Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay.

作者信息

Stürmer Martin, Berger Annemarie, Doerr Hans-Wilhelm

机构信息

Institut für Medizinische Virologie, J.W. Goethe Universität, Frankfurt, Germany.

出版信息

J Med Virol. 2003 Dec;71(4):475-9. doi: 10.1002/jmv.10527.

Abstract

Genotypic testing for HIV-1 resistance to anti-retroviral drugs has become accepted widely as a routine method to guide anti-retroviral therapy. However, implementation into routine high-throughput laboratory diagnosis is difficult due to the complexity of the assay. A commercially available assay is the ViroSeq HIV-1 Genotyping System (Applied Biosystems, Weiterstadt, Germany). We modified and substituted the RNA extraction module to optimize the proportion of samples amplified successfully as follows: 1 ml plasma was concentrated by ultracentrifugation and extracted according to the manufacturer's instructions (Kit), by substituting the lysis buffer (Roche, Roche Diagnostics GmbH, Mannheim, Germany), and by using the QIAamp Viral RNA Kit (Qiagen GmbH, Hilden, Germany) with elution volumes of 60 (Q60) or 50 micro l (Q50). Overall Q50 showed a higher success rate (97%) than the other extraction modules used (range 88-91%). In samples with a viral load range of 1,000-4,999 copies/ml, Q50 was superior (95 vs. 65% to 83%), while in samples with a viral load range of 5,000-9,999 copies/ml or those with 10,000 or more copies/ml, the success rate of the extraction procedures showed no significant differences. In 18 samples, which were negative using the Kit or Roche extraction, Q60 resulted in 7/18 positive results; in addition the Q50 was successful in amplifying 7/10 of the Q60 negative samples. When investigating samples with a measurable viral load of less than 1,000 copies/ml or lower, Q50 had the highest success rate with 80% compared to the other procedures (33-63%). A statistically significant new cut-off could be defined for Q50 at a value of 250 copies/ml. The results showed clearly that the ViroSeq System is suitable for analyzing the HIV-1 genotype over a wide range of viral loads but could be improved significantly when substituting the RNA extraction module with Q50 without using a nested PCR protocol. This is of great importance as it avoids further time- and cost-intensive steps.

摘要

HIV-1对抗逆转录病毒药物耐药性的基因分型检测已被广泛接受为指导抗逆转录病毒治疗的常规方法。然而,由于检测方法的复杂性,将其应用于常规高通量实验室诊断存在困难。一种市售检测方法是ViroSeq HIV-1基因分型系统(德国魏特施塔特应用生物系统公司)。我们对RNA提取模块进行了修改和替换,以优化成功扩增样本的比例,具体如下:1毫升血浆通过超速离心浓缩,并根据制造商的说明书(试剂盒)进行提取,用裂解缓冲液(德国曼海姆罗氏诊断有限公司罗氏公司)进行替换,并使用洗脱体积为60微升(Q60)或50微升(Q50)的QIAamp病毒RNA试剂盒(德国希尔德齐默尔公司)。总体而言,Q50的成功率(97%)高于所使用的其他提取模块(范围为88%-91%)。在病毒载量范围为1000-4999拷贝/毫升的样本中,Q50更具优势(分别为95%和65%-83%),而在病毒载量范围为5000-9999拷贝/毫升或病毒载量为10000拷贝/毫升及以上的样本中,提取程序的成功率没有显著差异。在18份使用试剂盒或罗氏提取法呈阴性的样本中,Q60产生了7/18个阳性结果;此外,Q50成功扩增了Q60阴性样本中的7/10。在检测病毒载量小于1000拷贝/毫升或更低的样本时,与其他程序(33%-63%)相比,Q50的成功率最高,为80%。可以为Q50定义一个具有统计学意义的新临界值,为250拷贝/毫升。结果清楚地表明,ViroSeq系统适用于在广泛的病毒载量范围内分析HIV-1基因型,但在不使用巢式PCR方案的情况下用Q50替换RNA提取模块时,可显著改进。这非常重要,因为它避免了进一步耗时和成本高昂的步骤。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验